Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Share-based Compensation (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Share-based Compensation for 9 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 88.51% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.3 million, a 45.12% increase, with the full-year FY2025 number at $11.3 million, up 45.12% from a year prior.
  • Share-based Compensation was $3.2 million for Q4 2025 at Akebia Therapeutics, down from $3.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $6.9 million in Q2 2022 to a low of $1.5 million in Q4 2023.
  • A 5-year average of $3.4 million and a median of $3.1 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: tumbled 50.21% in 2023, then soared 95.69% in 2025.
  • Akebia Therapeutics' Share-based Compensation stood at $4.6 million in 2021, then tumbled by 34.4% to $3.0 million in 2022, then crashed by 50.21% to $1.5 million in 2023, then rose by 12.09% to $1.7 million in 2024, then surged by 88.51% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Share-based Compensation are $3.2 million (Q4 2025), $3.2 million (Q3 2025), and $2.7 million (Q2 2025).